Dr. Reddy’s Laboratories: Basic Information
What is QVTQVT Stock Score
Dr. Reddy's Laboratories Ltd.Quality 55 /100 High Financial StrengthValuation 43 /100 Mid ValuationTechnicals 41 /100 Technically NeutralMid-range PerformerGoodAverageBad
Dr. Reddy's Laboratories Ltd.SWOT Analysis
What is SWOT AnalysisStrengthsWeaknessOpportunityThreatsWhat is SWOT Analysis ?These are then classified as strengths, weaknesses, opportunities that investors can leverage, and threats that might impact company health.Strengths, Weaknesses, Opportunities and Threats Analysis is a real time check on stock health throughout the day. SWOT looks at financials, management quality, technical parameters and valuations to identify positives and negatives for every stock.
- Strengths
- Weakness
- Opportunity
- Threats
- Price crossing above SMA20 today, and greater than SMA5
- Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE
- Buy Zone: Stocks in the buy zone based on days traded at current PE and P/BV
- Upcoming results with Rising Delivery Volumes
- Relative Outperformance versus Industry over 1 Month
- Relative Outperformance versus Industry over 1 Week
- Results Screener: Stocks with upcoming results which are seeing positive shifts in share price
- Relative Outperformance versus Industry over 1 Month
- Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
- Efficient in managing Assets to generate Profits - ROA improving since last 2 year
- Growth in Net Profit with increasing Profit Margin (QoQ)
- Companies with Low Debt
- Increasing Revenue every quarter for the past 3 quarters
- Annual Net Profits improving for last 2 years
- Book Value per share Improving for last 2 years
- Companies with Zero Promoter Pledge
- MACD crossed above signal line previous end of day
- Top Gainers
- PEG greater than Industry PEG
- Stocks Underperforming their Industry Price Change in the Quarter
- Companies with Upcoming Results
- Brokers upgraded recommendation or target price in the past three months
- Highest FII stock holdings
- MFs increased their shareholding last quarter
- Mutual Funds Increased Shareholding over the Past Two Months
- Red Flags: Firms linked to ongoing regulatory investigations/legal cases
Products and Services:
- Therapeutic Areas: Oncology, dermatology, diabetes, and cardiovascular diseases
- Generic Medicines: Affordable and high-quality formulations
- Specialty Products: Biosimilars, over-the-counter (OTC) drugs, and proprietary medicines
- Active Pharmaceutical Ingredients (APIs): Supplying APIs to pharmaceutical companies worldwide
Key Financial Metrics (as of 2024):
- Revenue: ₹25,000 crore (approx.)
- Net Profit: ₹3,800 crore (approx.)
- Market Capitalization: ₹90,000 crore (approx.)
Global Presence:
- Operations in over 50 countries
- Manufacturing facilities in India, the United States, and Europe
- Strong export portfolio, particularly in the US, Europe, and emerging markets
Recognition:
- Leader in biosimilars and oncology medicines
- Recognized for sustainable manufacturing practices
- Innovator in affordable healthcare and cutting-edge research
Two-Paragraph Introduction
Dr. Reddy’s Laboratories is a globally renowned pharmaceutical company dedicated to delivering affordable and innovative healthcare solutions. Founded in 1984 by Dr. Kallam Anji Reddy and headquartered in Hyderabad, Dr. Reddy’s specializes in a wide range of therapeutic areas, including oncology, dermatology, and diabetes. The company’s robust portfolio includes generic medicines, biosimilars, and proprietary drugs, along with active pharmaceutical ingredients (APIs) that cater to a global clientele. Dr. Reddy’s commitment to quality and innovation has positioned it as a trusted name in pharmaceuticals across over 50 countries.
Just as Reliance has revolutionized the telecom and energy sectors, Dr. Reddy’s Laboratories has transformed the pharmaceutical industry by making advanced therapies accessible to millions. With a focus on patient-centric solutions and sustainable practices, the company addresses some of the world’s most pressing healthcare challenges. Its cutting-edge research and global outreach continue to drive its mission of delivering “Good Health Can’t Wait,” solidifying its status as a leader in affordable and innovative healthcare.
Full Name: Dr. Reddy’s Laboratories Limited
Type: Public Sector Pharmaceutical Company
Headquarters: Hyderabad, Telangana, India
Founded: 1984
Founder: Dr. Kallam Anji Reddy
Chairman: G.V. Prasad (as of 2025)
CEO & MD: Erez Israeli (as of 2025)
Tagline: Good Health Can’t Wait
Industry: Pharmaceuticals and Biologics